VivoSeq
Infectious Disease

Endocarditis

17

Pipeline Programs↗

8

Active Trials↗

6

Companies Involved↗

Endocarditis is an emerging landscape with 17 programs across 6 companies. The most active players are Sanofi, Boehringer Ingelheim, Eli Lilly. 9 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

67/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

ApprovedPfizer logo

Pfizer

2 programs

ApprovedW

Watson Pharmaceuticals

1 program

PreclinicalS

Stefan Hagel

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

16

clinical trials

Completed4 · 25%
Not yet recruiting4 · 25%
Recruiting2 · 13%
Unknown status2 · 13%
Withdrawn1 · 6%
Enrolling by invitation1 · 6%
Other2 · 13%

Clinical Trials

Trial Activity

16 trials

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus
Recruiting·—·Phase 3·NCT07253688·330 enrolled
Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
Recruiting·FFundacion Clinic per a la Recerca Biomédica·Approved·NCT05398679·360 enrolled
ENDO-CARE: Endocarditis Clinical Awareness, Research, and Evaluation in Sweden
Active, not recruiting·KKarolinska Institutet·N/A·NCT07671118·22,000 enrolled
FOUR-SIX TRIAL for the Treatment of Enterococcal Endocarditis
Not yet recruiting·UUniversity Magna Graecia·Phase 4·NCT05398289·130 enrolled
Management of Anemia in Patients with EndocaRditis Infectious Candidates for Cardiac Surgery: the AMERICA Study
Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06583902·100 enrolled
Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
Not yet recruiting·NNantes University Hospital·Phase 3·NCT07345325·422 enrolled
Efficacy and Safety of Dalbavancin in the Treatment of Infective Endocarditis Caused by Gram-Positive Cocci
Not yet recruiting·—·Phase 3·NCT07699211·184 enrolled
Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
Enrolling by invitation·—·Phase 4·NCT05156437·20 enrolled
Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure
Completed·PPoitiers University Hospital·Phase 3·NCT02142075
Partial Oral Treatment of Endocarditis
Completed·—·Phase 4·NCT01375257·400 enrolled
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus
Completed·UUniversity Hospital, Tours·Phase 3·NCT02701595·324 enrolled
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
Completed·UUniversity Hospital, Tours·Phase 3·NCT02701608·162 enrolled
Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.
Terminated·WWeill Medical College of Cornell University·Phase 4·NCT00401960·6 enrolled
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
Withdrawn·LLysovant·Phase 2·NCT05329168
Hyperbaric Oxygen Treatment in Humans With Gram Positive Cocci Endocarditis
Unknown status·—·Phase 2·NCT04691440·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)